Retour sur lavenir.net
   ENERGYVISION 17.200 € (+5,91 %)     RETAIL ESTATES 66.500 € (+0,61 %)     SOFINA 252.000 € (+1,20 %)     KINEPOLIS GROUP 48.550 € (+0,83 %)     GIMV 44.800 € (0,00 %)     CMB.TECH 16.780 € (+4,09 %)     SOLVAY 26.180 € (+0,93 %)     VGP 79.300 € (-4,46 %)     CIE BOIS SAUVAGE 308.000 € (+2,67 %)     ASCENCIO 53.300 € (+0,57 %)     JENSEN-GROUP 75.600 € (+1,89 %)     WDP 21.640 € (-0,09 %)     ATENOR 1.200 € (-4,00 %)     TESSENDERLO 22.300 € (+0,68 %)     XIOR 27.050 € (+0,56 %)     SHURGARD 22.950 € (-0,22 %)     AGEAS 76.400 € (+0,13 %)     FLUXYS BELGIUM D 22.800 € (0,00 %)     TUBIZE-FIN 178.700 € (-3,92 %)     MONTEA 65.300 € (0,00 %)     EVS 29.200 € (-0,51 %)     AGFA-GEVAERT 0.421 € (-5,51 %)     ARGENX SE 893.600 € (-2,06 %)     ONWARD MEDICAL 2.505 € (+2,04 %)     BEKAERT 39.400 € (+1,68 %)     KBC 133.200 € (-0,30 %)     VASTNED 28.800 € (+0,52 %)     OPTION 3.880 € (-0,51 %)     MELEXIS 65.850 € (+1,15 %)     CARE PROPERTY INV. 12.620 € (+1,61 %)     GBL 73.950 € (+0,20 %)     BPOST 1.294 € (-0,46 %)     AB INBEV 69.040 € (+0,26 %)     FAGRON 21.650 € (-1,37 %)     HOME INVEST BE. 19.040 € (+1,17 %)     BIOTALYS 2.350 € (+1,29 %)     COLRUYT 39.520 € (-0,35 %)     IBA 15.660 € (-0,25 %)     LOTUS BAKERIES 12 220.000 € (0,00 %)     D'IETEREN GROUP 180.400 € (+3,44 %)     KBC ANCORA 95.200 € (+0,21 %)     SIPEF 104.200 € (0,00 %)     VAN DE VELDE 30.000 € (-0,33 %)     RECTICEL 12.900 € (+1,26 %)     TEXAF 41.000 € (-0,97 %)     TINC 11.240 € (+0,36 %)     EXMAR 11.550 € (+1,76 %)     CAMPINE 184.000 € (-0,81 %)     ACCENTIS 0.027 € (+3,85 %)     PROXIMUS 6.345 € (+0,87 %)     NYXOAH 1.496 € (+1,08 %)     CENERGY 22.960 € (-0,61 %)     BARCO 8.045 € (+1,77 %)     AZELIS GROUP 12.310 € (0,00 %)     TITAN S.A. 54.150 € (+1,03 %)     ACKERMANS V.HAAREN 280.600 € (+2,93 %)     ELIA GROUP 119.100 € (+0,34 %)     SYENSQO 81.350 € (-0,31 %)     CFE 11.150 € (0,00 %)     WERELDHAVE BELGIUM 50.600 € (-1,17 %)  
   INTRASENSE 0.288 € (+10,77 %)     SHELL PLC 40.105 € (+0,16 %)     ASML HOLDING 1 467.400 € (+3,09 %)     WOLTERS KLUWER 68.860 € (-2,44 %)     ALTEN 72.450 € (-5,60 %)     TOTALENERGIES 76.100 € (-2,46 %)     ASM INTERNATIONAL 825.200 € (+6,20 %)     MONCEY (FIN.) NOM. 115.000 € (-0,43 %)     SHOWROOMPRIVE 0.960 € (+6,19 %)     VALNEVA 2.955 € (-1,96 %)     SAINT GOBAIN 75.780 € (+0,37 %)     NEXANS 136.600 € (-1,44 %)     AIR LIQUIDE 170.440 € (-1,34 %)     DASSAULT AVIATION 277.400 € (-0,07 %)     ESSILORLUXOTTICA 149.800 € (-2,06 %)     REXEL 36.120 € (+1,69 %)     AUREA 6.000 € (+1,69 %)     BNP PARIBAS ACT.A 104.540 € (+0,38 %)     BE SEMICONDUCTOR 196.650 € (+2,74 %)     ADYEN 1 026.600 € (-1,57 %)     FOUNTAINE PAJOT 83.400 € (-0,60 %)     IPSOS 36.820 € (-6,88 %)     L'OREAL 383.900 € (+1,43 %)     BOLLORE 3.824 € (-3,68 %)     MAGNUM 16.702 € (-1,12 %)     AKZO NOBEL 60.740 € (+0,07 %)     BOIRON 26.000 € (+1,56 %)     UMG 14.245 € (-1,28 %)     CARREFOUR 16.405 € (+0,46 %)     STMICROELECTRONICS 44.805 € (+1,77 %)     ALTAREA 91.000 € (-0,44 %)     GETLINK SE 18.610 € (+0,16 %)     Coca-ColaEuropacif 91.500 € (-2,24 %)     CATERING INTL SCES 20.500 € (-3,30 %)     TIKEHAU CAPITAL 16.800 € (0,00 %)     HEINEKEN 73.020 € (+0,38 %)     DERICHEBOURG 9.210 € (+1,38 %)     SCHNEIDER ELECTRIC 288.000 € (+0,23 %)     ORANGE 15.340 € (-0,42 %)     VINCI 113.950 € (+0,71 %)     AKWEL 6.300 € (-0,32 %)     BUREAU VERITAS 27.200 € (-0,18 %)     HERMES INTL 1 457.000 € (-1,65 %)     MEDINCELL 22.800 € (-1,30 %)     VOLTALIA 5.310 € (-0,75 %)     XILAM ANIMATION 4.940 € (-1,20 %)     ALSTOM 16.500 € (+2,01 %)     DASSAULT SYSTEMES 21.020 € (-6,49 %)     ARCELORMITTAL SA 67.240 € (+2,41 %)     CHRISTIAN DIOR 393.800 € (+0,92 %)     VEOLIA ENVIRON. 31.900 € (+0,28 %)     CAPGEMINI 106.400 € (-3,27 %)     GECINA 68.200 € (+0,15 %)     STELLANTIS NV 4.780 € (+1,59 %)     ATOS GROUP 26.820 € (-1,76 %)     CASINO GUICHARD 0.185 € (+1,32 %)     CROSSJECT 1.340 € (-4,69 %)     SOITEC 128.300 € (+3,89 %)     ACCOR 46.900 € (+2,47 %)     KERING 245.200 € (+0,25 %)  
News Réglementées
09/01/2023 20:00

The Power Play by The Market Herald Releases a New Interview with Algernon Pharmaceuticals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / January 9, 2023 / The Power Play by The Market Herald has announced the release of a new interview with Algernon Pharmaceuticals discussing their latest news.

The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

Algernon Pharmaceuticals (CSE:AGN) announces upcoming phase 2b chronic cough study of Ifenprodil
The Market Herald, Monday, January 9, 2023, Press release picture

Algernon Pharmaceuticals (AGN) has announced plans for a 180-patient, 90-day Phase 2b clinical study of NP-120 for chronic cough in Q3 of 2023. Following discussions with the U.S. FDA, the company plans to file an investigational new drug (IND) application shortly. Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the upcoming study.

For the full interview with Christopher J. Moreau and to learn about Algernon Pharmaceuticals, click here.

Interviews for The Power Play by The Market Herald are released daily. To learn more about the companies featured in The Power Play or to explore our other interviews visit The Power Play by The Market Herald.

About The Market Herald

The Market Herald Canada is the leading source of authoritative breaking stock market news for self-directed investors. Our team of Canadian markets reporters, editors and technologists covers the entire listed company universe in Canada. We cover over 3,985 businesses, their people, their investors, and their customers. We write the stories that move the Canadian capital markets.

DISCLAIMER: Report Card Canada Media Ltd. ("Report Card") is a wholly-owned subsidiary of Market Herald Limited, an Australian company ("Market Herald"). Report Card is not an advisory service, and does not offer, buy, sell, or provide any other rating, analysis or opinion on the securities we discuss. We are retained and compensated by the companies that we provide information on to assist them with making information available to the public. All information available on themarketherald.ca and/or this press release should be considered as commercial advertisement and not an endorsement, offer or recommendation to buy or sell securities. Report Card is not registered with any financial or securities regulatory authority in any province or territory of Canada, will not be performing any registerable activity as defined by the applicable regulatory bodies and do not provide nor claim to provide investment advice or recommendations to any visitor of this site or readers of any content on or originating from themarketherald.ca. Market Herald and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Market Herald's affiliates. In such instances, Market Herald and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Market Herald and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize any conflict. All the information on this document and/or the website - themarketherald.ca - is published in good faith and for general information purpose only. Report Card does not make any warranties about the completeness, reliability, and accuracy of this information. Any action you take upon the information you find on this document and/or website (themarketherald.ca) is strictly at your own risk. Report Card will not be liable for any losses and/or damages in connection with the use of our website. From our website, you can visit other websites by following hyperlinks to such external sites. While we strive to provide only quality links to useful and ethical websites, we have no control over the content and nature of these sites. These links to other websites do not imply a recommendation for all the content found on these sites. Site owners and content may change without notice and may occur before we have the opportunity to remove a link which may have gone 'bad'. Please be also aware that when you leave our website, other sites may have different privacy policies and terms which are beyond our control. Please be sure to check the Privacy Policies of these sites as well as their "Terms of Service" before engaging in any business or uploading any information.

CONTACT:
The Market Herald
marketing@themarketherald.ca
themarketherald.ca

SOURCE: The Market Herald



View source version on accesswire.com:
https://www.accesswire.com/734527/The-Power-Play-by-The-Market-Herald-Releases-a-New-Interview-with-Algernon-Pharmaceuticals-Discussing-Their-Latest-News

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière